Literature DB >> 824724

Inhibition of prostaglandin biosynthesis by tolfenamic acid in vitro.

I B Lindén, J Parantainen, H Vapaatalo.   

Abstract

The effect of tolfenamic acid on prostaglandin biosynthesis was investigated by using rabbit kidney medulla microsomal fraction, and the results compared with those obtained with indomethacin and acetylsalicylic acid. Tolfenamic acid inhibited the conversion of arachidonic acid to prostaglandin E2 very effectively and in a dose-dependent manner. IC50 values were 0.64 muM for tolfenamic acid, 0.76 muM for indomethacin, and 7 mM for acetylsalicylic acid. The inhibition of prostaglandin biosynthesis may be related to the good anti-inflammatory action of tolfenamic acid.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 824724     DOI： 10.3109/03009747609165450

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


  10 in total

1.  Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent.

Authors:  P J Pentikäinen; P J Neuvonen; C Backman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

2.  Pharmacokinetics of tolfenamic acid in pediatric patients after single oral dose.

Authors:  I Niopas; M Georgarakis; V Sidi-Frangandrea; C Chrisanthopoulos; E Liara
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

3.  Orally administered tolfenamic acid inhibits leukotriene synthesis in isolated human peripheral polymorphonuclear leukocytes.

Authors:  E Moilanen; J Alanko; A Juhakoski; H Vapaatalo
Journal:  Agents Actions       Date:  1989-08

4.  Effects of nonsteroidal anti-inflammatory drugs on rat gastric mucosal phosphodiesterase activity.

Authors:  J Silvola; M Kangasaho; O Tokola; H Vapaatalo
Journal:  Agents Actions       Date:  1982-10

Review 5.  Non-steroidal anti-inflammatory analgesics other than salicylates.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

6.  Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates.

Authors:  R G Khalifah; C E Hignite; P J Pentikäinen; A Penttilä; P J Neuvonen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

7.  Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid.

Authors:  R A Tokola; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

8.  Oral antipyretic therapy: evaluation of the N-aryl-anthranilic acid derivatives mefenamic acid, tolfenamic acid and flufenamic acid.

Authors:  S Keinänen; S Similä; K Kouvalainen
Journal:  Eur J Clin Pharmacol       Date:  1978-07-30       Impact factor: 2.953

9.  Pharmacokinetics of tolfenamic acid in patients with cirrhosis of the liver.

Authors:  J Stenderup; J Eriksen; S B Pedersen; L V Christiansen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease.

Authors:  M Láznícek; K E Senius
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.